A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Latest Information Update: 19 Jan 2019
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 24 May 2018 Status changed from recruiting to discontinued due to accrual factor
- 09 Jan 2018 Planned End Date changed from 31 Dec 2017 to 31 Jul 2019.